Clinical trial
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome…
NCT00380250 · Sucampo Pharma Americas, LLC, Industry · Completed
Key facts
| NCT number | NCT00380250 |
|---|---|
| Title | Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation |
| Official title | Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation |
| Lead sponsor | Sucampo Pharma Americas, LLC, Industry |
| Collaborators | Takeda Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome With Constipation |
| Intervention type | Drug |
| Interventions | Lubiprostone, Placebo |
| Enrollment | 590 |
| Start date | May 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Sep 25, 2006 |
| Last update posted | Nov 15, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: